Takeda Signs Agreement With Galaxy Biotech for HuL2G7

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 8
Volume 15
Issue 8

Takeda Pharmaceutical has signed an exclusive licensing agreement with Galaxy Biotech (Mountain View, California) to develop, manufacture, and market HuL2G7, a recombinant humanized anti-hepatocyte growth factor (anti-HGF) monoclonal antibody developed by Galaxy Biotech. HGF is believed to mediate proliferation, metastasis, antiapoptosis, and neoangiogenesis of many types of tumors. In animal models, treatment of intracranial glioma xenografts with HuL2G7 induced substantial tumor regression and prolonged survival (Clin Cancer Res 12:1292-1298, 2006).

TOKYO, Japan—Takeda Pharmaceutical has signed an exclusive licensing agreement with Galaxy Biotech (Mountain View, California) to develop, manufacture, and market HuL2G7, a recombinant humanized anti-hepatocyte growth factor (anti-HGF) monoclonal antibody developed by Galaxy Biotech. HGF is believed to mediate proliferation, metastasis, antiapoptosis, and neoangiogenesis of many types of tumors. In animal models, treatment of intracranial glioma xenografts with HuL2G7 induced substantial tumor regression and prolonged survival (Clin Cancer Res 12:1292-1298, 2006).

Articles in this issue
Younger Age at Brain Tumor Diagnosis Portends Poor Emotional Outcome
Higher Responses in Metastatic Colon Ca When Cetuximab Added to Chemo
Triple Targeted Therapy Is Tested in Pts With Solid Tumors
FDA Approves Three-Drug Combination Tablet for HIV-1
Side Effects Persist 16 Years After Prostate Ca Brachytherapy
No Significant QOL Differences for Raloxifene and Tamoxifen
Amrubicin Appears Promising in Small-Cell Lung Cancer
R-MP Active in Older Pts With Newly Diagnosed Myeloma
Sunitinib and Sorafenib Active in Phase II Advanced NSCLC Trials
Takeda Signs Agreement With Galaxy Biotech for HuL2G7
Experimental Regimens Fail to Boost Pancreatic Survival
Adding Bortezomib Ups Dual Transplant Results in Myeloma
Demand Spurs Efforts to Improve Recruitment, Retention
Why Has Mortality Related to Pancreatectomy Declined?
Phase III Trial Finds XP as Efficacious as EP as First-Line Therapy for Metastatic Breast Cancer
Related Videos
ZAP-X may provide submillimeter accuracy when administering radiation to patients with brain tumors.
Related Content
The FDA approval of the single-agent, oral pan-RAF inhibitor tovorafenib is based on efficacy results from the phase 2 FIREFLY-1 trial.

FDA Approves Tovorafenib for Relapsed/Refractory Low-Grade Glioma

April 23rd 2024
Article

The FDA approval of the single-agent, oral pan-RAF inhibitor tovorafenib is based on efficacy results from the phase 2 FIREFLY-1 trial.

Javier Orozco-Mera, MD, FACS, MSc, discusses signaling pathways and molecular mechanisms involved in the relapse of glioblastoma.

Oncology-On-The-Go Podcast: Signaling Pathways in Glioblastoma Relapse

May 1st 2023
Podcast

Javier Orozco-Mera, MD, FACS, MSc, discusses signaling pathways and molecular mechanisms involved in the relapse of glioblastoma.

First-in-patient findings support AZD1390 as a potential radiosensitizer during the management of glioblastoma.

AZD1390/Radiation Yields Encouraging Efficacy, Safety in Glioblastoma

April 9th 2024
Article

First-in-patient findings support AZD1390 as a potential radiosensitizer during the management of glioblastoma.

Promising Glioma Therapy Options

Promising Glioma Therapy Options

December 21st 2018
Podcast

Dr. James Perry speaks with Cancer Network about glioma therapy options and the future of brain cancer treatment.

Findings from a phase 1b trial support the tolerability and potential survival benefit of CAN-3110 as a treatment for patients with recurrent high-grade glioma.

CAN-3110 Earns FDA Fast Track Designation in Recurrent High-Grade Glioma

February 13th 2024
Article

Findings from a phase 1b trial support the tolerability and potential survival benefit of CAN-3110 as a treatment for patients with recurrent high-grade glioma.

Eflornithine, which was approved in adult and pediatric patients with high-risk neuroblastoma, was assessed in an externally controlled trial comparing results in both Study 3b and Study ANBL0032.

Eflornithine Is Approved by the FDA for High-Risk Neuroblastoma

December 13th 2023
Article

Eflornithine, which was approved in adult and pediatric patients with high-risk neuroblastoma, was assessed in an externally controlled trial comparing results from Study 3b and Study ANBL0032.